P53 and PTEN expression evaluation with molecular evident recent criteria in laryngeal carcinoma

Simple item page
dc.contributor.authorTan A.
dc.contributor.authorEskiizmir G.
dc.contributor.authorKamiloglu U.
dc.contributor.authorSarioglu S.
dc.date.accessioned2024-07-22T08:02:48Z
dc.date.available2024-07-22T08:02:48Z
dc.date.issued2023
dc.description.abstractThe prognosis of laryngeal cancer is affected by clinicopathological factors. Because of that, an effective prognostic marker is very valuable in managing the clinical process. The p53 evaluation method, used in the literature recently, was used for the first time in laryngeal cancer. We evaluated PTEN with 2 methods with the highest significance in the literature on laryngeal cancer. All demographic and histopathological data from 140 laryngeal cancers were compared with p53 and PTEN expressions and survival. p53 staining patterns were classified as wild and mutant. PTEN expression was evaluated according to the staining intensity named PTEN1 and according to the proportion of stained cells named PTEN2. In the series, 93.6% were males, and the mean survival was 38 months. 69.3% of cases were p53 mutants. PTEN loss was found to be 85.7% and 57.9%, respectively. Tumor size and thyroid cartilage invasion for PTEN1 and age for p53 were identified as independent predictive factors (P <.01). Advanced age, total laryngectomy, and extranodal spread were independent poor prognostic factors for overall survival and the presence of subglottic involvement, perineural invasion, and extranodal spread were for disease-free survival (P <.01). This is the first study in which the new p53 classification was used in laryngeal cancer, and will contribute significantly to the literature with differences from the previous evaluation patterns. Evaluation of PTEN based on staining intensity is more appropriate compared to the percentage of stained cells. © Copyright 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
dc.identifier.DOI-ID10.1097/MD.0000000000033676
dc.identifier.issn00257974
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11999
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectCarcinoma
dc.subjectFemale
dc.subjectHumans
dc.subjectLaryngeal Neoplasms
dc.subjectMale
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectPTEN Phosphohydrolase
dc.subjectTumor Suppressor Protein p53
dc.subjectphosphatidylinositol 3,4,5 trisphosphate 3 phosphatase
dc.subjectprotein p53
dc.subjectphosphatidylinositol 3,4,5 trisphosphate 3 phosphatase
dc.subjectprotein p53
dc.subjectPTEN protein, human
dc.subjectadult
dc.subjectArticle
dc.subjectcancer prognosis
dc.subjectcancer size
dc.subjectcancer surgery
dc.subjectcancer survival
dc.subjectcontrolled study
dc.subjectdisease free survival
dc.subjectfemale
dc.subjectfollow up
dc.subjectgene expression
dc.subjecthistopathology
dc.subjecthuman
dc.subjectlaryngectomy
dc.subjectlarynx cancer
dc.subjectlarynx carcinoma
dc.subjectlarynx squamous cell carcinoma
dc.subjectlymph node metastasis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoverall survival
dc.subjectperineural invasion
dc.subjectpreoperative radiotherapy
dc.subjectprotein expression
dc.subjectthyroid cartilage
dc.subjecttotal laryngectomy
dc.subjecttumor suppressor gene
dc.subjecttumor volume
dc.subjectcancer staging
dc.subjectcarcinoma
dc.subjectgenetics
dc.subjectlarynx tumor
dc.subjectmetabolism
dc.subjectpathology
dc.subjectprognosis
dc.titleP53 and PTEN expression evaluation with molecular evident recent criteria in laryngeal carcinoma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu